in

Biopharmaceutical company: Navidea Biopharmaceuticals, Inc. (NAVB)

Navidea Biopharmaceuticals, Inc. (NASDAQ:NAVB) was founded in 1983, formerly known as Neoprobe Corporation, and changed to its current name in January 2012. It is headquartered in Dublin, Ohio, and has 19 full-time employees. It is a biopharmaceutical company with a focus on For the development and commercialization of precise immunodiagnostics and immunotherapeutics.

Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NAVB):

Navidea Biopharmaceuticals is a leader in precision medicine. Its products have immuno-targeted products designed to help identify the locations and pathways of undetected diseases, improve diagnosis accuracy, clinical decision-making, targeted treatment, and patient care.

Navidea Biopharmaceuticals applies the company’s Manocept™ technology, Navidea is committed to developing next-generation targeted diagnosis and treatment for cancer, autoimmune diseases and other inflammatory diseases.

Navidea Biopharmaceuticals is divided into two departments to operate : Diagnostic Substances and Therapeutic Development Programs.

Navidea Biopharmaceuticals has developed:

  • Manocept platform to target and activate the CD206 mannose receptor expressed on macrophages.
  • NAV4694, a fluorine-18 labeled positron emission tomography imaging agent, is used to assist in imaging and evaluating patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment.
  • The company is also developing NAV5001, an iodine-123-labeled single-photon emission computed tomography imaging agent for the diagnosis of Parkinson’s disease and other movement disorders, and may be used as a diagnostic aid for dementia.
  • Diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and treatment development plans, such as the treatment application of its Manocept platform, and various development plans.
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Clinical stage biotechnology company: Shattuck Labs, Inc. (STTK) (2016)

Emission reduction technology and specialty chemicals company: Advanced Emissions Solutions, Inc. (ADES) (1996)